Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Moderna (MRNA) closed at $58.39 in the latest trading session, marking a -0.56% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Elsewhere, the Dow saw an ...

The rise in mRNA pharmaceuticals’ licensing agreement values suggests that this field will remain a major area for innovation ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

The Centers for Disease Control and Prevention (CDC) currently recommends that everyone aged 6 months and up get the Moderna or Pfizer COVID-19 vaccines. The Novavax vaccine is authorized by the U.S.

Analysis - Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

In the late 1980s, Ambros and Ruvkun were postdoctoral researchers in the laboratory of Robert Horvitz, who received the ...

Penn Engineers have discovered a simple and inexpensive means of directing lipid nanoparticles (LNPs), the revolutionary ...

Most investors unaware of the huge breakthroughs happening in biotech right now. But new technologies such as cancer-killing ...

The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...